| Editor's Choice: Heart Health | It could cost more than $1 million just to avoid a single heart attack, stroke or cardiovascular death, researchers wrote. It could cost more than $1 million just to avoid a single heart attack, stroke or cardiovascular death, researchers wrote. | |
| Medicare enrollees paid a total of $3.4 billion in out-of-pocket costs for these drugs in 2022 alone, according to new data shared by the White House. Medicare enrollees paid a total of $3.4 billion in out-of-pocket costs for these drugs in 2022 alone, according to new data shared by the White House. | |
| The complaint describes Medtronic's actions as “immoral, unethical, oppressive and unscrupulous.” The complaint describes Medtronic's actions as “immoral, unethical, oppressive and unscrupulous.” | |
| The FDA found that the seeds are actually yellow oleander, a poisonous plant known to contain cardiac glycosides. The FDA found that the seeds are actually yellow oleander, a poisonous plant known to contain cardiac glycosides. | |
| Programs managed by H-E-B, Kroger, Mark Cuban Cost Plus Drug Company and Walmart appear to offer the most options for CVD patients. When it comes to AFib and heart failure, however, researchers believe the choices could be improved. Programs managed by H-E-B, Kroger, Mark Cuban Cost Plus Drug Company and Walmart appear to offer the most options for CVD patients. When it comes to AFib and heart failure, however, researchers believe the choices could be improved. | |
| The Body Scan Connected Health Station includes a high-strength glass platform with four weight sensors and 14 ITO electrodes and a retractable handle with four stainless steel electrodes. The Body Scan Connected Health Station includes a high-strength glass platform with four weight sensors and 14 ITO electrodes and a retractable handle with four stainless steel electrodes. | |
| A few members of the panel did question the device's efficacy and long-term durability. The FDA will now use these findings to make its final decision related to the system's approval. A few members of the panel did question the device's efficacy and long-term durability. The FDA will now use these findings to make its final decision related to the system's approval. | |
| The ACC has joined forces with Amgen and Esperion Therapeutics to increase LDL screening in patients with and without a history of cardiovascular issues. The ACC has joined forces with Amgen and Esperion Therapeutics to increase LDL screening in patients with and without a history of cardiovascular issues. | |
| The vote was close, initially ending with a tie, but the panel ultimately decided there were too many questions related to the device's long-term benefits for patients with uncontrolled hypertension. The vote was close, initially ending with a tie, but the panel ultimately decided there were too many questions related to the device's long-term benefits for patients with uncontrolled hypertension. | |
| |
|
| | |
|